Nazmiye Türker

Nazmiye Türker

Auto-generated profile, based on publicly available information

Nazmiye Türker

Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Journal of Pediatric Intensive Care
Verified
Journal Article
Closed access
PDF file
EGemrah gün
emrah gün
TKTANIL KENDIRLI
TANIL KENDIRLI
EBEdin Botan
Edin Botan
NTNazmiye Türker
Nazmiye Türker
AGAnar Gurbanov
Anar Gurbanov
EÇErgin Çiftçi
Ergin Çiftçi
Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU). Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated. Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8–14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2–5) and only one patient died. Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.

5 November 2026 in Turkish Archives of Pediatrics
Verified
Journal Article
Closed access
PDF file
NTNazmiye Turker
Nazmiye Turker
SÖSonay İnCesoy Özdemir
Sonay İnCesoy Özdemir
TUTayfun Uçar
Tayfun Uçar
EUEmel Unal
Emel Unal
HDHandan Dinçaslan
Handan Dinçaslan
NTNurdan Tacyildiz
Nurdan Tacyildiz
Objective: Anthracycline-based chemotherapy is used in 50%-60% of childhood cancers despite well-known cardiotoxicity. The authors evaluated dexrazoxane (DEX) as a cardioprotective agent in children receiving anthracyclines. Methods: The authors retrospectively analyzed 142 children aged 0-18 years treated for childhood cancer. The control group comprised 87 patients who received anthracycline alone (2009-2019) and the case group 55 patients who received DEX + anthracycline (2019-2022, after DEX was licensed in Türkiye). Cardiac dysfunction was defined as a left ventricular ejection fraction (LVEF) below 50%. Results: Baseline LVEF was comparable. Mean LVEF fell by 0.71 Å} 6.55 points with DEX vs. 6.44 Å} 9.76 in controls (Time Å~ Group interaction F(1,140) = 14.77, P < .001), and the difference persisted after adjustment for follow-up duration and treatment covariates (β = +4.60, 95% CI = 1.10-8.10, P = .010). Cardiac dysfunction developed in 11 of 87 controls (12.6%) and in none of the 55 DEX patients (P = .007; log-rank P = .040); this held in a 36-month landmark analysis (0 of 52 vs. 4 of 25, P = .009). Mortality was higher in controls (21.8% vs. 5.5%, P = .009) and in patients with cardiac dysfunction (54.5% vs. 17.1%, P = .012). Conclusion: Dexrazoxane attenuated the early decline in LVEF and reduced the incidence of anthracycline-induced cardiotoxicity, and this persisted after adjustment for the difference in follow-up duration. With a median DEX follow-up of only 22.8 months, these data support early cardioprotection; longer follow-up is needed to assess protection against late-onset cardiotoxicity.